Phosphodiesterase 5 inhibitors (PDE5i) vs placebo
Patient‐reported pain intensity or pain relief (VAS, NRS or categorical scale) · adults with Raynaud's phenomenon (primary or secondary)
1 finding from 1 review
- Phosphodiesterase 5 inhibitors (PDE5i) for the treatment of Raynaud's phenomenon 2023 · Cochrane Headline outcomes onlyno estimate extractedStudies not reportedLow